Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of AtriCure, Inc. (NASDAQ:ATRC)

Key Points

• Representative Gilbert Ray Cisneros, Jr. purchased between $1,001 and $15,000 in shares of AtriCure, Inc. (NASDAQ:ATRC) on May 6th, as disclosed in a recent filing.
• AtriCure has a market capitalization of $1.49 billion with its stock price fluctuating between a 12-month low of $20.20 and a high of $43.11.
• Wall Street analysts have a consensus price target of $50.67 for AtriCure, with several firms maintaining a "buy" rating despite recent target price reductions.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on June 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in AtriCure stock on May 6th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
• Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
• Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
• Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
• Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
• Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.

AtriCure Price Performance

Shares of ATRC stock traded down $0.36 during trading hours on Tuesday, hitting $32.87. 243,658 shares of the company's stock were exchanged, compared to its average volume of 568,720. The company has a quick ratio of 2.88, a current ratio of 4.11 and a debt-to-equity ratio of 0.16. The firm has a market cap of $1.63 billion, a P/E ratio of -40.56 and a beta of 1.56. The firm has a 50 day moving average of $32.29 and a two-hundred day moving average of $34.32. AtriCure, Inc. has a fifty-two week low of $20.20 and a fifty-two week high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative return on equity of 5.68% and a negative net margin of 7.95%. The business had revenue of $123.62 million during the quarter, compared to the consensus estimate of $122.92 million. During the same period in the prior year, the company posted ($0.28) EPS. The business's quarterly revenue was up 13.5% on a year-over-year basis. Sell-side analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on ATRC. Needham & Company LLC reduced their price objective on AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. JMP Securities reissued a "market outperform" rating and issued a $60.00 price objective on shares of AtriCure in a research note on Wednesday, April 30th. UBS Group reduced their price objective on AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Finally, Wall Street Zen downgraded AtriCure from a "buy" rating to a "hold" rating in a research note on Sunday, June 1st. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.67.

Hedge Funds Weigh In On AtriCure

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. boosted its stake in shares of AtriCure by 0.8% in the 4th quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after buying an additional 334 shares during the period. Perkins Capital Management Inc. lifted its stake in AtriCure by 1.3% during the fourth quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock worth $927,000 after purchasing an additional 400 shares during the last quarter. Truist Financial Corp lifted its stake in AtriCure by 2.6% during the fourth quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock worth $480,000 after purchasing an additional 403 shares during the last quarter. State of Wyoming lifted its stake in AtriCure by 21.9% during the fourth quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after purchasing an additional 446 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in AtriCure by 5.4% during the fourth quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock worth $350,000 after purchasing an additional 584 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Insiders Place Their Bets

In related news, insider Vinayak Doraiswamy sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $33.44, for a total transaction of $83,600.00. Following the completion of the sale, the insider owned 73,550 shares in the company, valued at $2,459,512. The trade was a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.50% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.